This article examines current evidence supporting the use of neoadjuvant immunotherapy in patients with resectable macroscopic stage III melanoma and critically discusses the selection of appropriate adjuvant therapy following surgery. It is written in the context of emerging evidence from ...

The 2026 World Conference on Lung Cancer delivered several results with the potential to change clinical practice. My main takeaway was the speed at which effective options are multiplying in both small-cell lung cancer and molecularly defined non-small-cell lung cancer. The immediate advance is welcome, but it also makes treatment selection more complex: mature survival, intracranial control, toxicity, sequencing and access will increasingly matter as much as response rate or progression-free survival.

Circulating tumor DNA (ctDNA) has emerged as an innovative and minimally invasive tool in precision oncology. With a short half-life of 30–120 min, ctDNA provides real-time insight into tumor dynamics.1 In early-stage breast cancer, there is growing evidence supporting its potential ...

Join us as leading experts discuss key data from the Plenary, Late-breaking and top oral sessions across each major disease area at ASCO 2026 touchONCOLOGY coverage of ASCO 2026 2026 American Society of Clinical Oncology (ASCO) Annual Meeting brought together the global oncology ...

Extended follow-up from the phase 3 INDIGO trial presented at ASCO 2026 provides further evidence that vorasidenib may offer durable disease control in patients with grade 2 glioma harboring IDH1/2 mutations, reinforcing earlier findings that led to its regulatory approvals. In the article below, we provide a details analysis of the latest INDIGO data and Dr Timothy Cloughesy's expert perspective on what the longer-term efficacy and safety findings could mean for the evolving treatment landscape in IDH-mutant glioma.

Several late-breaking gastrointestinal oncology studies presented at ASCO 2026 highlighted how treatment selection is continuing to evolve across colorectal, hepatobiliary, gastric, and esophageal cancers, with new data on ctDNA-guided adjuvant therapy, earlier integration of targeted agents, and intensified perioperative strategies. In this round-up, we have selected six of the most important late-breakers, and examine the latest data from CIRCULATE, BREAKWATER, EMERALD-3, Neo-CRAG, SCIENCE, and RC48-C027.

At ASCO 2026 several neuro-oncology presentations focused less on introducing entirely new paradigms and more on defining where existing and emerging therapies may best fit. Across brain metastases and glioma, phase 3 data addressed longstanding practical questions around radiation delivery, chemotherapy duration, and local therapies, while updated targeted therapy data in IDH-mutant glioma continued to mature. In this piece, Dr Rimas Lukas highlights four main abstracts from ASCO 2026, discussing their take-aways and considering their potential relevance for clinical practice.

At AAN 2026, Dr Jigisha Thakkar presented data challenging long-standing assumptions of continuous tumor growth and suggesting that some patients may benefit from more individualized surveillance and treatment strategies. In this Q&A, Dr Thakkar discusses how intermittent dormancy in IDH-mutant gliomas may influence clinical decision-making, from MRI surveillance intervals to the timing of therapeutic intervention.

ASCO 2026 showed that thoracic oncology is moving beyond promising signals and increasingly closer to practice-changing evidence across multiple fields — from bispecific antibodies and ADC-based combinations to targeted therapy in both metastatic and peri-operative settings. In this piece, Dr Federico Monaca breaks down eight major abstracts from ASCO26, highlighting their take-aways and considering their potential relevance for clinical practice.